tiprankstipranks
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
AVBP
ArriVent BioPharma, Inc.
RESEARCH TOOLSreports

ArriVent BioPharma, Inc. (AVBP) Stock News & Sentiment

78 Followers
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
Premium
Company Announcements
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
24d ago
8K
AVBP
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
Premium
Ratings
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
1M ago
AVBP
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
Premium
Ratings
ArriVent Therapeutics: Late-Stage Firmonertinib Data and Differentiated Profile Support Buy Rating and Upside Potential
3M ago
AVBP
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
Premium
Ratings
ArriVent Buy Rating: Favorable Risk‑Reward on Firmonertinib Ahead of Pivotal FURVENT Phase 3 Readout
3M ago
AVBP
3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
4M ago
AMZN
APGE
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment
Premium
Ratings
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment
4M ago
AVBP
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results
Premium
Ratings
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results
4M ago
AVBP
More AVBP News >

AVBP News on the Web

JonesTrading Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
TipRanks News
Neutral
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Zacks
Bullish
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Zacks
Bullish
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
TipRanks News
Bullish
ArriVent Highlights Next-Generation Oncology Data at AACR 2026
TipRanks News
Bullish
ArriVent Biopharma assumed with a Buy at BTIG
TipRanks News
Bullish
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
TipRanks News
Bullish
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
Zacks
Neutral

News Score - Last 7 Days

Neutral
AVBP
Sector Average
Media Buzz
This Week2 articles
Weekly Average1.25 articles
News Sentiment
This Week100%
Sector Average69%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is AVBP’s Media Buzz Sentiment?
2 articles about AVBP were published this week. In an average week, 1.25 articles are published.
    What is AVBP’s weekly average amount of articles?
    In an average week, 1.25 articles about AVBP are published.
      What is AVBP’s News Sentiment?
      100% of articles about AVBP were positive this week, compared to its sector average of 69%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week